Senti Biosciences stock rating initiated at Buy by H.C. Wainwright

Investing.com - H.C. Wainwright initiated coverage on Senti Biosciences, Inc. (NASDAQ:SNTI) with a Buy rating and a price target of $12.00 on Tuesday. The micro-cap biotech company, currently valued at $44 million, has seen its shares decline nearly 49% over the past six months, though InvestingPro analysis suggests the stock is currently undervalued.

The research firm highlighted Senti’s allogeneic, "off-the-shelf," CAR-NK cell therapy platform that uses proprietary gene circuit technology to treat various cancer types including hematologic malignancies and solid tumors.

H.C. Wainwright noted that Senti’s lead candidate SENTI-202, developed for acute myeloid leukemia (AML), has shown promising efficacy with a 71% (5/7) overall response rate and 57% (4/7) composite complete remission rate without severe adverse events typically associated with CAR-T therapies.

The firm emphasized SENTI-202’s potential advantage through its OR/NOT logic-gated CARs design, which targets CD33 and/or FLT3 antigens in AML while preventing off-target toxicity, addressing a disease area with no currently approved cell therapies.

According to H.C. Wainwright, Senti Biosciences shares are trading near cash value, with additional data from approximately 15-20 patients expected in the fourth quarter of 2025 that could further validate the company’s gene circuit platform. The company will report its next earnings on November 10, 2025. Discover more key financial metrics and insights with InvestingPro, which offers 8 additional ProTips for SNTI.

In other recent news, Senti Biosciences has completed the dose-finding phase for its SENTI-202 therapy in an ongoing Phase 1 clinical trial targeting relapsed/refractory acute myeloid leukemia (AML). The company has confirmed the recommended Phase 2 dose and is now enrolling additional patients in the dose expansion phase of the trial. Additionally, Senti Bio announced that it will present its logic-gated CAR-NK cell therapy at the BioScience Forum in San Carlos, California. The presentation will be delivered by Kanya Rajangam, the President, Head of Research & Development, and Chief Medical Officer of Senti Bio. Furthermore, Senti Biosciences has appointed Bryan Baum, Co-Founder and Managing Partner of K5 Global, to its Board of Directors. Baum brings a wealth of entrepreneurial experience, having founded and sold multiple ventures, including Parrot and Blue Vision Labs. These developments reflect the company’s ongoing efforts in advancing its therapeutic pipeline and strengthening its leadership team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.